Manufacturers announce positive results from the CheckMate -649 phase III trial investigating nivolumab and chemotherapy vs chemotherapy alone in first line treatment of gastric and oesophageal cancers

Nivolumab was linked to superior overall survival and progression free survival when used in combination with FOLFOX vs FOLFOX alone in non-HER2-positive, advanced or metastatic gastric cancer or oesophageal adenocarcinoma. Data from nivolumab and ipilimumab arm are awaited.

Biospace Inc.